Cymirafen is a novel antibody-drug conjugate (ADC) from the University of California that targets leucine-rich repeat-containing G-protein coupled receptor 4 (LGR4)/LGR5/LGR6 and is composed of a potent cytotoxic payload, monomethyl auristatin E (MMAE), plus an Fc domain fused to the receptor binding domain of RSPO1.
Researchers from Cogent Biosciences Inc. presented the preclinical profile of CGT-1263, a pan-KRAS-directed compound that binds both ON and OFF KRAS conformations without affecting HRAS or NRAS.
Researchers from Elpiscience Biopharmaceuticals Inc. hypothesized that dual targeting of the TL1A/DR3 and IL-23 signaling pathways with a single bispecific antibody would exert superior efficacy by reshaping the immune landscape in disorders such as inflammatory bowel disease (IBD). The company has developed a bispecific antibody targeting both TL1A/DR3 and IL-23p19 – ES-302 – for the treatment of IBD.
The Global Health Innovative Technology (GHIT) Fund has invested in a number of R&D projects for the development of drugs for malaria, including a global partnership led by Medicines for Malaria Venture (MMV), Tanabe Pharma Corp. and the University of Georgia.
Flagship Pioneering Inc. has announced the launch of Serif Biomedicines Inc., a biotechnology company pioneering modified DNA as a new class of medicines. Modified DNA brings together the best features of mRNA and gene therapy, while mitigating their limitations, by enabling medicines that are programmable, scalable, durable and redosable.
Klebsiella pneumoniae and Acinetobacter baumannii are both major contributors to the global antimicrobial resistance crisis, causing rapidly progressive and often severe infections. Researchers from Vaxdyn SL and collaborators presented efficacy data for K-Vax, an inactivated, LPS-null whole-cell A. baumannii-based vaccine engineered to display conserved K. pneumoniae outer-membrane proteins on the bacterial cell surface.
Neolaia Inc. has divulged new quinoline- and quinazoline-carboxamide derivatives acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of atherosclerosis, cancer, inflammation, obesity, Alzheimer’s, autoimmune, cardiovascular and metabolic disorders.
Insilico Medicine Inc. has reported new NLRP3 inflammasome inhibitors potentially useful for the treatment of obesity, autoimmune and autoinflammatory diseases.
The National Center of Neurology and Tokyo University of Science in Japan have jointly developed new μ-opioid receptor antagonists potentially useful for the treatment of opioid dependence.
RSS
